In Brief: Knoll Mavik
Knoll Mavik: ACE inhibitor trandolapril gains new indication for use in stable patients who have evidence of left-ventricular systolic dysfunction or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. The recommended starting dose for the indication is 1 mg once daily, with titration to a target dose of 4 mg once daily...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth